FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer.
Casak SJ, Kumar V, Song C, Yuan M, Amatya AK, Cheng J, Mishra-Kalyani PS, Tang S, Lemery SJ, Auth D, Davis G, Kluetz PG, Pazdur R, Fashoyin-Aje LA.
Casak SJ, et al. Among authors: yuan m.
Clin Cancer Res. 2024 Jun 10. doi: 10.1158/1078-0432.CCR-24-0517. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38856639